Market revenue in 2023 | USD 70.4 million |
Market revenue in 2030 | USD 99.0 million |
Growth rate | 5% (CAGR from 2023 to 2030) |
Largest segment | Anti-infective |
Fastest growing segment | Chemotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti-Infective, Endocrinology, Hydration Therapy, Chemotherapy, Enteral Nutrition, Parenteral Nutrition, Specialty Pharmaceuticals |
Key market players worldwide | CVS Group PLC, Walgreens Boots Alliance Inc, UnitedHealth Group Inc, BrightSpring Health Services Inc, Fresenius Medical Care AG, ICU Medical Inc, B. Braun Medical, Baxter International Inc, BD, Smiths Group PLC, Terumo Corp, Caesarea Medical Electronics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to home infusion therapy market will help companies and investors design strategic landscapes.
Anti-infective was the largest segment with a revenue share of 26.7% in 2023. Horizon Databook has segmented the Israel home infusion therapy market based on anti-infective, endocrinology, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition, specialty pharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
According to World Bank Group, the country’s population aged 65 & above accounted for nearly 11.7% of the total population in 2017 and around 12.2% in 2019. Rise in geriatric population is anticipated to increase the demand for long-term and home care services, thereby fueling the market growth. Chronic diseases were responsible for 60% of the deaths in 2017 Heart diseases and cancer, together accounted for nearly 42% of all deaths, according to the Ministry of Health in Israel.
The prevalence of multi-chronic conditions was 27.3% and is associated with the increase in life expectancy of the people. In addition, in 2018, the Ministry of Health announced that it will establish new procedures to shift from hospital care to home care, which is expected to boost the market. Increasing prevalence of chronic diseases along with supportive government initiatives is anticipated to propel the market growth.
Furthermore, any company that markets pharmaceutical products or equipment to the Israeli healthcare system (such as hospitals & health patient funds) is required to comply with the new regulations pertaining to sales & marketing interactions between the company and healthcare setting in Israel. These new regulations are anticipated to increase the marketing & sales challenges for market players.
Horizon Databook provides a detailed overview of country-level data and insights on the Israel home infusion therapy market , including forecasts for subscribers. This country databook contains high-level insights into Israel home infusion therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account